| 2.76 -0.04 (-1.43%) | 01-30 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 4.01 |
1-year : | 4.49 |
| Resists | First : | 3.43 |
Second : | 3.84 |
| Pivot price | 3.32 |
|||
| Supports | First : | 2.75 |
Second : | 2.29 |
| MAs | MA(5) : | 2.9 |
MA(20) : | 3.28 |
| MA(100) : | 3.21 |
MA(250) : | 3.1 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 1.9 |
D(3) : | 5.5 |
| RSI | RSI(14): 33.3 |
|||
| 52-week | High : | 6.57 | Low : | 1.37 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ SERA ] has closed above bottom band by 5.9%. Bollinger Bands are 52.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.88 - 2.91 | 2.91 - 2.93 |
| Low: | 2.7 - 2.74 | 2.74 - 2.76 |
| Close: | 2.72 - 2.78 | 2.78 - 2.81 |
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Sun, 01 Feb 2026
Will Sera Prognostics Inc. stock benefit from upcoming earnings reports - July 2025 Selloffs & Daily Entry Point Trade Alerts - mfd.ru
Fri, 30 Jan 2026
Sera Prognostics (NASDAQ:SERA) Shares Down 2.8% - Here's Why - MarketBeat
Tue, 27 Jan 2026
Insider Sell Alert: Robert Harrison Sells 2,000 Shares of Sera P - GuruFocus
Sat, 24 Jan 2026
We Think Sera Prognostics (NASDAQ:SERA) Needs To Drive Business Growth Carefully - Sahm
Sun, 11 Jan 2026
Sera Prognostics CEO sells $64,463 in stock - MSN
Wed, 07 Jan 2026
Sera Prognostics, Inc. Publishes PRIME Study Results - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 2.68e+007 (%) |
| Held by Institutions | 10.6 (%) |
| Shares Short | 391 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.617e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -56 % |
| Return on Assets (ttm) | 125 % |
| Return on Equity (ttm) | -24.8 % |
| Qtrly Rev. Growth | 95000 % |
| Gross Profit (p.s.) | -45.26 |
| Sales Per Share | -48.18 |
| EBITDA (p.s.) | -59596 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -26 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.06 |
| Price to Cash Flow | 1.28 |
| Dividend | 0 |
| Forward Dividend | 298450 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|